A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

Inclusion Criteria: * Participant's parent(s)/Legally acceptable representative(s) \[LAR(s)\], who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., return for follow-up visits). * Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the participant prior to performance of any study specific procedure. * Healthy participants as established by medical history and clinical examination before entering the study. * Born full term (i.e., after a gestation period of ≥37 weeks). Exclusion Criteria: * Current or previous, confirmed or suspected disease caused by N. meningitidis. * Known exposure from birth to an individual with laboratory confirmed N. meningitidis infection. * Progressive, unstable or uncontrolled clinical conditions. * Any contraindications to group B meningococcal vaccine, including but not limited to: history of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention. * Medical conditions representing a contraindication to intramuscular vaccination and blood draws. * Any neuroinflammatory condition (including but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), any congenital neurological condition, encephalopathies, seizures (including all subtypes such as: absence seizures, generalized tonic-clonic seizures, partial complex seizures, partial simple seizures). * Congenital or peripartum disorders…